AM-Pharma - Gilde Healthcare



Utrecht, The Netherlands

Drug Development
Since: 2014

AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).

The company successfully completed a phase 2 study and has initiated the global phase III REVIVAL pivotal study of recombinant human Alkaline Phosphatase in 1400 patients in more than 100 hospitals in twelve countries in Europe and the United States. SA-AKI is a major unmet medical need which involves an inflammatory process in the kidney which can lead to complete loss of renal function and affects annually approximately 3 million patients in Europe, US and Japan and is associated with the death of 700.000 patients per year.

Gilde invested to finance the phase II clinical study in 2014 and subsequently participated in the €139M financing round in 2020 to finance the REVIVAL phase III study.

AM-Pharma is located in Utrecht (Netherlands).

More AM-Pharma news

Gilde Healthcare company AM-Pharma initiates Phase 2 trial of Ilofotase alfa for cardiac surgery-associated renal damage

Gilde Healthcare company AM-Pharma announces positive clinical data from Phase 1b study evaluating ilofotase alfa in hypophosphatasia patients

Gilde Healthcare company AM-Pharma announces updated clinical development strategy

AM-Pharma announces enrollment and financing of COVID-19 cohort in phase III REVIVAL trial

AM-PHARMA Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

AM-Pharma Raises Record Financing of €116m [$133m] for Phase III Trial in Acute Kidney Injury

AM-Pharma announces Phase II study results of recap in sepsis-associated Acute Kidney Injury

AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase (recAP) Phase II trial in Acute Kidney Injury

AM-Pharma signs $600 million acquisition option with Pfizer

AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury

Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia

AM-Pharma Closes €12.2 million Financing Round